You are here

P&T News

October 21

Experts anticipate launch of first therapies for geographic atrophy
Reference pricing aims to cut costs
Safety involves three key principles

October 20

Flexible custom mask covers hollow eye socket at lower cost
Morphine/naltrexone combo expected to reduce oral abuse when crushed
Disease ignored by public, neglected by doctors, experts say

October 17

Studies will prepare vaccine candidate for clinical trials
Top-line results released in NIH-funded comparison of effectiveness
British research focused on the role of enzymes in bacteria
Progressive scarring of lungs leaves patients short of breath

October 16

New data support efficacy of chimeric antigen receptor therapy
Medications and nonpharmacologic recommendations graded
Longer period might be needed to prevent virus spread, expert says

October 15

Additional exposures were expected, agency says
Novel antipsychotic and improved rescue therapy take center stage by 2023
Replaceable device allows urination without catheterization

October 14

Approval decision expected in April 2015
Soliris takes the prize at nearly $537,000 per year
Modified sulfonylurea stimulates insulin release
Drug’s effect on weight change, sexual function similar to that of placebo

October 13

Drug’s effect on weight change, sexual function similar to that of placebo

October 13

Living-cell bioformulation fails to provide significant improvement
Health care worker is first to develop disease in U.S.
Harvard discovery could help prevent clotting and infections
Certain patients with genotype-1 infections need just 8 weeks of treatment

October 12

Living-cell bioformulation fails to provide significant improvement
Health care worker is first to develop disease in U.S.
Harvard discovery could help prevent clotting and infections

October 10

Author identifies financial constraints on antibiotic research
Array of genetic defects thwart targeted treatments

October 8

Symptoms and severity of the illness are frightening, expert admits
Oral nucleotide analog demonstrates antiviral activity

Pages

P&T TV

“Very Impressive Data” for Rose Bengal 10% in Intralesional Melanoma

Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, says a phase 2 trial of Rose Bengal 10% as a chemical ablative agent injected directly into melanoma tumors yielded “very impressive data.” Even “bystander” lesions that were not injected showed good partial and complete responses, confirming the agent’s systemic value. Because of low toxicity, the treatment could be useful not only in combination with other therapies but as monotherapy for patients who aren’t good candidates for more toxic systemic treatments.

American Society of Clinical Oncology

Meetings

Nashville, TN
November 3 to November 4
Brussels, Belgium
November 12 to November 14

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.